Press Releases

2014

2013

2012

2011

Tryton Announces DRG Reimbursement Code For Side Branch Stent in Germany New Code Signals Growing Market Acceptance for Side Branch Stents

Tryton Announces Successful Live Case Transmission at TCT Conference in San Francisco Data Presentations Highlight Consistently Positive Clinical Results

Tryton Announces Clinical Presentations at TCT Conference in San Francisco Company to Exhibit at TCT in Booth #1927

IVUS Cohort Recruitment Complete in Landmark Tryton IDE Study More Than 175 Patients Enrolled in Multi-National Pivotal Trial

Tryton’s Innovative Solution Highlighted at Annual European Bifurcation Club Meeting Tryton Medical’s TRYTON Side Branch Stent™ System was discussed as an important new therapeutic option for patients with bifurcation disease last week at the annual European Bifurcation Club (EBC) meeting.

Tryton Announces Positive Data from Three European Registries

Tryton Announces Positive Data from Three European Registries Results Show Low MACE and TLR Rates, No Late Stent Thrombosis; Session at EuroPCR Highlights Stent System as Potential Treatment for Left Main Disease

Shawn P. McCarthy Appointed President and Chief Executive Officer of Tryton Medical, Inc.

Tryton Announces CE Mark for Larger-Diameter Sizes of Side Branch Stent New Sizes Will Allow Physicians to Treat Broader Group of Patients with Bifurcation Disease

Tryton Announces Enrollment of First U.S. Patient in Pivotal Study of Side Branch Stent Study Is the First Randomized Multi-Center Bifurcation Trial in the United States

2010

Tryton Announces Enrollment of First Patient in U.S. Pivotal Study of Side Branch Stent Study to Enroll 704 Patients At Up To 75 Centers in North America and Europe

Tryton Announces Investigational Device Exemption Conditional Approval from FDA to Conduct U.S. Pivotal Study of Side Branch Stent Study to Enroll 700 Patients At Up To 75 Centers in North America and Europe

Clinical Study Featuring Tryton Stent Wins Best Abstract Award at Italian Society of Interventional Cardiology National Congress (GISE) in Genoa, Italy Live Case Transmission During Conference Demonstrates Ease-of-Use of Tryton Stent System

Tryton Announces First Patient Enrollment in E-Tryton Italy Registry of the Tryton Side Branch Stent System Study To Assess Real-Life Clinical Results in 300 Patients With Bifurcation Disease in Italy

Tryton Announces Positive Six-Month Results for Side Branch Stent System Results Consistently Demonstrate a Rate of Target Lesion Revascularization of Less Than Four Percent in More Than 400 Patients

Tryton Announces TCT Activities Symposium to Feature Interim Six-Month Results from More Than 250 Patients Treated with Tryton Stent System

Tryton Completes $20 Million Financing To Accelerate U.S. Pivotal Trial Strong Support from Current Investors and New Investor Arnerich Massena & Associates

Tryton Announces Launch in Several European and Eastern European Countries Excellent Six-Month Clinical Results with Target Lesion Revascularization Rate of Less Than Four Percent

Tryton Announces First Implants in Israel More Than 1,300 Patients Treated Worldwide with Tryton Stent System

Tryton Announces Positive Data from Side Branch System Presented in Symposium at EuroPCR 2010 Tryton Stent Consistently Demonstrates Excellent Results

Shawn P. McCarthy Appointed President and CEO



Tryton Announces Enrollment Completion of Two European Registries Studies Will Assess Tryton Side-Branch Stent in Real-World Settings More than 1,000 Patients Treated with Tryton System

Tryton Stent Implanted in First Cases in Portugal and Austria Company Celebrates 750th Implant

2009

2008

2007

2006